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Although the presence of tumor-infiltrating lymphocytes
(TILs) indicates an endogenous anti-tumor response,
immune regulatory pathways can subvert the effector
phase and enable tumor escape. One possible negative
regulatory pathway is T cell-intrinsic anergy. Recently,
we have shown that the transcription factor Egr2 is criti-
cal in controlling the anergic state using an in vitro
model system. Gene expression profiling and Egr2 ChIP-
Seq analysis revealed multiple Egr2-driven cell surface
proteins in T cell anergy, including the inhibitory recep-
tor LAG-3, but also the costimulatory receptor 4-1BB.
We examined whether these surface proteins identify
dysfunctional tumor-reactive CD8+ T cells. A major
population of CD8+ TILs co-expressing 4-1BB and LAG-
3 was observed in the “progressor” tumor models B16
and C1498 but not the spontaneously rejected “regressor”
MC57.SIY model. Kinetic analysis showed the appear-
ance and persistence of this population over time only in
the tumor. Upon ex vivo stimulation the 4-1BB+LAG-3+
as well as CD8+Egr2GFP+ TILs exhibited a significant
reduction in IL-2 production compared to their negative
counterpart indicating TIL dysfunction. TCR repertoire
analysis showed CDR3b skewing in the 4-1BB+LAG-3+
compartment, indicating oligoclonality. In addition, CD8
+ TIL specific for the model antigen SIY expressed LAG-
3 and 4-1BB. Further, 2C T cells transferred into a tumor
bearing host upregulated LAG-3 and 4-1BB within 3 days
after entering the tumor. These data confirmed that the
vast majority of tumor-reactive CD8+ TILs express 4-1BB
and LAG-3. Although the 4-1BB+LAG-3+ TIL population
lacked the ability to produce IL-2, high levels of IFN-g,
GzmB, Perforin, IL-10 as well as the Treg-recruiting che-
mokines CCL1 and CCL22 were produced by this popu-
lation. These data argue that this population may exert
negative immunomodulatory functions and not be com-
pletely inert. Therapeutic targeting of this population by
agonistic 4-1BB and blocking LAG-3 mAb combination
resulted in increased tumor control and an overall shift
towards short term effector KLRG1hiIL7Rlo phenotype in
CD8+ TILs as well as decreased expression of several
inhibitory receptors including PD-1 and 2B4. Interest-
ingly, ex vivo stimulation of CD8+ TILs after treatment
resulted in restoration of the ability to produce IL-2. Our
results suggest that the co-expression of LAG-3 and 4-
1BB identifies a critical subpopulation of dysfunctional
tumor antigen-specific CD8+ TILs and may contribute to
an immune suppressive tumor microenvironment. Inhibit-
ing LAG-3 while agonizing 4-1BB resulted in an increased
anti-tumor response and a significant change in phenotype
and function in the CD8+ TIL compartment.
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